NASDAQ:PHVS Pharvaris (PHVS) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free PHVS Stock Alerts $23.11 -0.39 (-1.66%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$21.16▼$23.6150-Day Range$21.26▼$32.0752-Week Range$7.00▼$33.00Volume8,740 shsAverage Volume108,351 shsMarket Capitalization$735.82 millionP/E RatioN/ADividend YieldN/APrice Target$32.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Pharvaris alerts: Email Address Pharvaris MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside40.6% Upside$32.50 Price TargetShort InterestHealthy0.15% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.30) to ($2.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.71 out of 5 starsMedical Sector493rd out of 938 stocksPharmaceutical Preparations Industry224th out of 423 stocks 3.3 Analyst's Opinion Consensus RatingPharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.50, Pharvaris has a forecasted upside of 40.6% from its current price of $23.11.Amount of Analyst CoveragePharvaris has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.15% of the float of Pharvaris has been sold short.Short Interest Ratio / Days to CoverPharvaris has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pharvaris has recently decreased by 85.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPharvaris does not currently pay a dividend.Dividend GrowthPharvaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PHVS. Previous Next 3.0 News and Social Media Coverage News SentimentPharvaris has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Pharvaris this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Pharvaris to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pharvaris insiders have not sold or bought any company stock.Percentage Held by Insiders11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pharvaris are expected to grow in the coming year, from ($2.30) to ($2.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pharvaris is -7.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pharvaris is -7.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPharvaris has a P/B Ratio of 4.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders ExposedThis consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. About Pharvaris Stock (NASDAQ:PHVS)Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Read More PHVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHVS Stock News HeadlinesMarch 20, 2024 | americanbankingnews.comPharvaris' (PHVS) "Outperform" Rating Reaffirmed at WedbushMarch 19, 2024 | americanbankingnews.comCritical Review: Pharvaris (NASDAQ:PHVS) & Verrica Pharmaceuticals (NASDAQ:VRCA)March 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 18, 2024 | globenewswire.comPharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesMarch 6, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesMarch 5, 2024 | globenewswire.comPharvaris to Participate in the Leerink Global Biopharma Conference 2024February 26, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE TreatmentFebruary 25, 2024 | msn.comPharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 22, 2024 | finance.yahoo.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 22, 2024 | globenewswire.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 16, 2024 | finance.yahoo.comPharvaris Announces Extraordinary Meeting of ShareholdersFebruary 16, 2024 | globenewswire.comPharvaris Announces Extraordinary Meeting of ShareholdersFebruary 14, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)January 26, 2024 | finance.yahoo.comPharvaris to Present at the WSAAI Annual Meeting 2024January 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris with Increased Price Target Following FDA Regulatory AdvancesJanuary 23, 2024 | finance.yahoo.comPharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE ProgramJanuary 22, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksJanuary 22, 2024 | msn.comPharvaris rises as FDA lifts hold on hereditary angioedema candidateJanuary 22, 2024 | markets.businessinsider.comPharvaris Says FDA Lifts Clinical Hold On IND For Deucrictibant For Treatment Of HAE AttacksJanuary 22, 2024 | finance.yahoo.comPharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksJanuary 17, 2024 | seekingalpha.comPharvaris: Digging Deep For Sufficient Market SizeJanuary 9, 2024 | markets.businessinsider.comPositive Clinical Trials and Strong Financial Position Support Buy Rating for PharvarisJanuary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris Amid Anticipated Clinical Updates and Positive Trial ProspectsJanuary 5, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesJanuary 5, 2024 | finance.yahoo.comPharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesDecember 17, 2023 | msn.comPharvaris (PHVS) Price Target Increased by 38.65% to 32.93See More Headlines Receive PHVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PHVS CUSIPN/A CIK1830487 Webwww.pharvaris.com Phone31-71-203-6410FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$32.50 High Stock Price Target$49.00 Low Stock Price Target$11.00 Potential Upside/Downside+40.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-80,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.83% Return on Assets-62.67% Debt Debt-to-Equity RatioN/A Current Ratio10.46 Quick Ratio10.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.94 per share Price / Book4.68Miscellaneous Outstanding Shares31,840,000Free FloatN/AMarket Cap$735.82 million OptionableNot Optionable Beta-3.12 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Berndt Axel Edvard Modig CPA (Age 65)M.B.A., Co-Founder, CEO & Executive Director Comp: $543.05kMs. Anna Nijdam M.Sc. (Age 43)R.A., Head of Strategic Finance & Principal Accounting Officer Ms. Joan Schmidt J.D. (Age 60)Chief Legal Officer Dr. Peng Lu M.D. (Age 46)Ph.D., Chief Medical Officer Dr. Anne A. Lesage Ph.D. (Age 63)Chief Early Development Officer Dr. Morgan Conn Ph.D. (Age 55)Chief Business Officer Mr. Wim Souverijns Ph.D. (Age 53)Chief Community Engagement & Commercial Officer Dr. Stefan Abele Ph.D. (Age 54)Chief Technology Operations Officer Maryann CiminoDirector of Corporate RelationsMs. Annick Deschoolmeester (Age 51)Chief Human Resources Officer More ExecutivesKey CompetitorsGrifolsNASDAQ:GRFSLAVA TherapeuticsNASDAQ:LVTXMainz BiomedNASDAQ:MYNZNLS PharmaceuticsNASDAQ:NLSPProcaps GroupNASDAQ:PROCView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 8,549 shares on 3/1/2024Ownership: 0.000%Price T Rowe Associates Inc. MDBought 842,698 shares on 2/16/2024Ownership: 0.000%Novo Holdings A SBought 210,000 shares on 2/15/2024Ownership: 4.835%Citadel Advisors LLCBought 141,458 shares on 2/15/2024Ownership: 0.444%Blackstone Inc.Bought 100,000 shares on 2/15/2024Ownership: 0.314%View All Institutional Transactions PHVS Stock Analysis - Frequently Asked Questions Should I buy or sell Pharvaris stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHVS shares. View PHVS analyst ratings or view top-rated stocks. What is Pharvaris' stock price target for 2024? 4 equities research analysts have issued 1-year price targets for Pharvaris' shares. Their PHVS share price targets range from $11.00 to $49.00. On average, they predict the company's stock price to reach $32.50 in the next year. This suggests a possible upside of 40.6% from the stock's current price. View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts. How have PHVS shares performed in 2024? Pharvaris' stock was trading at $28.05 on January 1st, 2024. Since then, PHVS stock has decreased by 17.6% and is now trading at $23.11. View the best growth stocks for 2024 here. Are investors shorting Pharvaris? Pharvaris saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 14,900 shares, a drop of 85.3% from the February 29th total of 101,600 shares. Based on an average daily volume of 110,500 shares, the short-interest ratio is presently 0.1 days. Currently, 0.2% of the shares of the company are short sold. View Pharvaris' Short Interest. When is Pharvaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our PHVS earnings forecast. How were Pharvaris' earnings last quarter? Pharvaris (NASDAQ:PHVS) issued its earnings results on Wednesday, November, 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.10. When did Pharvaris IPO? Pharvaris (PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers. Who are Pharvaris' major shareholders? Pharvaris' stock is owned by a number of institutional and retail investors. Top institutional shareholders include venBio Partners LLC (15.45%), Bain Capital Life Sciences Investors LLC (0.00%), Viking Global Investors LP (11.49%), Novo Holdings A S (4.83%), Price T Rowe Associates Inc. MD (2.65%) and Price T Rowe Associates Inc. MD (0.00%). How do I buy shares of Pharvaris? Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHVS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.